Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Island PharmaceuticalsASX:ILA -1.08%28 3-Year EPS without NRI Growth Rate is 8.50% as of Dec. 2025, which is 59% below its 10-year median of 20.70. GuruFocus rates ASX:ILA with a GF Score™ of 28/100. The stock has 3 warning signs investors should review. Among 1,161 Biotechnology companies, Island Pharmaceuticals ranks worse than 59.86% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 8.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 5 years, the highest 3-Year average EPS without NRI Growth Rate of Island Pharmaceuticals was 32.90% per year. The lowest was 8.50% per year. And the median was 20.70% per year.
Island Pharmaceuticals (ASX:ILA) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Island Pharmaceuticals 3-Year EPS without NRI Growth Rate Related Terms
ASX:ILA vs VRTX, REGN, RVMD: 3-Year EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, Island Pharmaceuticals's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Island Pharmaceuticals 3-Year EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Island Pharmaceuticals's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Island Pharmaceuticals's 3-Year EPS without NRI Growth Rate falls into.
Island Pharmaceuticals 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 8.50% mean?
Island Pharmaceuticals (ASX:ILA) has a 3-Year EPS without NRI Growth Rate of 8.50% as of Dec. 2025. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Island Pharmaceuticals and its competitors. This is 59% below median its historical median of 20.70. Over the past decade, Island Pharmaceuticals' 3-Year EPS without NRI Growth Rate has ranged from 8.50 to 32.90. According to the industry distribution chart, Island Pharmaceuticals ranks #695 out of 1161 companies in the Biotechnology industry, placing it in the top 59.9%.
Is Island Pharmaceuticals' 3-Year EPS without NRI Growth Rate too high?
Island Pharmaceuticals' current 3-Year EPS without NRI Growth Rate of 8.50% is 59% below median its 10-year median of 20.70. Over the past 10 years, this metric has ranged from a low of 8.50 to a high of 32.90. The Biotechnology industry median 3-Year EPS without NRI Growth Rate is 16.20. Island Pharmaceuticals' value of 8.50% is 47.5% below this industry median. Based on the distribution chart, Island Pharmaceuticals ranks #695 out of 1161 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Island Pharmaceuticals has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Island Pharmaceuticals' 3-Year EPS without NRI Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Island Pharmaceuticals ranks #695 out of 1161 companies for 3-Year EPS without NRI Growth Rate. This places Island Pharmaceuticals in the lower half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 16.20. Island Pharmaceuticals' value of 8.50% is 47.5% below this benchmark. Historically, Island Pharmaceuticals' own 3-Year EPS without NRI Growth Rate has ranged from 8.50 to 32.90 over the past decade. While the company's 10-year median is 20.70 vs. the industry median of 16.20, Island Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Biotechnology company?
The median 3-Year EPS without NRI Growth Rate among Biotechnology companies is 16.20, based on 1,161 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Island Pharmaceuticals's current 3-Year EPS without NRI Growth Rate of 8.50% is 47.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Island Pharmaceuticals and its competitors. For the Biotechnology industry, the median 3-Year EPS without NRI Growth Rate is 16.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Island Pharmaceuticals's current 3-Year EPS without NRI Growth Rate is 8.50%, which is 59% below median its own 10-year median of 20.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Island Pharmaceuticals stock overvalued right now?
Island Pharmaceuticals (ASX:ILA) has a current 3-Year EPS without NRI Growth Rate of 8.50%. The current 3-Year EPS without NRI Growth Rate is 8.50%, which is 59% below median its 10-year median of 20.70 and 47.5% below the Biotechnology industry median of 16.20. Island Pharmaceuticals' overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Island Pharmaceuticals (ASX:ILA), the current 3-Year EPS without NRI Growth Rate is 8.50% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Island Pharmaceuticals Ltd is a drug research and repurposing company focused on developing preventative or therapeutic drugs for viral infections, public health, or biosecurity threats. The company is following a dual development plan for its assets, ISLA-101 and Galidesivir. Its product candidate, ISLA-101, is being repurposed for the prevention and treatment of dengue fever and other mosquito-borne (or vector) borne diseases. Galidesivir is a clinical-stage antiviral molecule with a broad spectrum of activity in over 20 RNA viruses, including high-priority threats such as Ebola, Marburg, MERS, Zika, and Yellow fever viruses, with unmet medical needs. The company operates in a single segment, being research and development activities in Australia and the United States of America.
28GF Score
Get the complete analysis for ASX:ILA
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ILA has been successfully added to your 
